72 results about "Uricacidemia" patented technology

Disclosed in the present invention is an siRNA for inhibiting the expression of a urate transporter 1 (URAT1) gene in human cells. In the present invention, a plurality of siRNAs capable of inhibiting URAT1 expression are obtained by screening, and on this basis, appropriate modifications are performed to obtain sequences with improved target silencing ability. Drugs with the siRNAs as active ingredients are expected to be clinically applicable in the prevention and treatment of diseases related to the URAT1 target, such as gout, hyperuricemia, gouty arthritis and renal calculi.

The invention belongs to the technical field of biological medicine, and relates to application of a clerodendranthus spicatus tea bag in regulating intestinal excretion and reducing uric acid. One of the purposes of the invention is to provide the application of the clerodendranthus spicatus teabag in regulating intestinal tracts to reduce uric acid According to a preferred embodiment, the clerodendranthus spicatus teabag regulates ATP binding cassette transporter G2 and inhibits uricase activity. The invention provides the application of the clerodendranthus spicatus teabag in regulating the intestinal microbial environment and reducing uric acid, and the clerodendranthus spicatus teabag has remarkable beneficial effects. The clerodendranthus spicatus teabag can effectively regulate the structure and the function of intestinal microflora, especially the enrichment amount of characteristic bacteria Muriaculum in the intestinal tract, further strengthens the probiotic activity of the intestinal flora, and is helpful for maintaining the steady state of uric acid in the body. The multi-way synergistic effect not only provides an innovative strategy for preventing and treating hyperuricemia and related metabolic diseases, but also avoids side effects possibly brought by traditional medicines, and shows good application prospects and clinical values.

The invention belongs to the field of biological medicine, and particularly relates to application of urolithin D in preparation of medicine for relieving hyperuricemia. It is found for the first time that the urolithin D can significantly reduce the level of serum uric acid, improve the expression disorder of a kidney urate transporter, efficiently relieve or treat hyperuricemia and related diseases thereof, and relieve kidney injury and fibrosis; and the compound can be used for preparing medicines for treating hyperuricemia and related diseases, is low in cost and good in safety, and has a wide application prospect.

The invention relates to the technical field of traditional Chinese medicines, and discloses application of an active ingredient of shiny-leaved yellowhorn leaves in preparation of a medicine for treating hyperuricemia. The xanthoceras sorbifolia leaf active ingredients comprise quercitrin, rutin and myricetin; the content of quercitrin is 0.2508 mg / g to 0.6719 mg / g, the content of rutin is 0.6707 mg / g to 1.5831 mg / g, and the content of myricetin is 0.8002 mg / g to 3.4858 mg / g. According to the invention, myricetin, quercitrin and rutin are determined as core effective substances of shiny-leaved yellowhorn leaves for treating hyperuricemia for the first time; the multi-target and multi-channel action mechanism is disclosed; meanwhile, network pharmacological analysis shows that the three components have high connectivity in a network and jointly act on key targets such as XOD, ACE, AKR1B1 and TNF, it is prompted that the three components do not act singly, but play a treatment role through multi-target and multi-channel cooperation, the traditional'single target-single drug 'thinking is changed into a'multi-component-multi-target-multi-channel' system regulation mode, and the treatment effect is improved. A new thought is provided for comprehensive treatment of the hyperuricemia.

The present invention provides a pharmaceutical composition comprising a therapeutically effective amount of allopurinol, febuxostat, or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating cardiovascular disease, in which the composition is administered to a subject having a serum uric acid level of 6 mg / dl or higher to reduce the serum uric acid level of the subject to less than 6 mg / dl. Therefore, the pharmaceutical composition according to the present invention exhibits an excellent effect on xanthine oxidase inhibitor and is administered to selected subjects to effectively treat or prevent cardiovascular disease.

The invention belongs to the field of medical chemistry, and relates to a benzopyrone compound, a benzopyrone composition and application of the benzopyrone compound and the benzopyrone composition in preparation of a medicine for treating hyperuricemia. The chemical structure is as shown in formula I; in the formula, R1 is fluorine or hydrogen; r2 is fluorine or hydrogen; r3 is hydrogen, nitryl or tertiary butyl; r4 is hydrogen, fluorine or trifluoromethyl; and R1, R2, R3 and R4 are not hydrogen at the same time. The benzopyrone compound provided by the invention has good inhibitory activity on XOD, and can reduce the level of uric acid, thereby being beneficial to treatment of hyperuricemia.

This invention discloses an early screening system and method for hyperuricemia based on fingertip blood uric acid detection. The system includes a fingertip blood collection module, a detection module, a data processing module, a storage module, an analysis module, an early warning module, a display module, a communication module, a calibration module, and a power supply module. It accurately collects fingertip blood samples from subjects, obtains blood uric acid concentration data using specific detection equipment, constructs a multi-dimensional analysis model based on clinical characteristic parameters, and determines the optimal diagnostic cutoff value based on ROC curves, achieving rapid and accurate screening for hyperuricemia. The method includes steps such as sample collection, detection, data processing, model analysis, result determination, and early warning. It is simple to operate, fast, and highly accurate, solving the problems of poor compliance and difficulty in grassroots implementation associated with traditional venous blood testing. It is suitable for large-scale population screening and early diagnosis of hyperuricemia in areas with scarce medical resources, and has significant clinical application value and social significance.

This invention belongs to the field of traditional Chinese medicine technology, specifically relating to a traditional Chinese medicine composition, its preparation method, and its uses. By mass parts, the raw materials of the traditional Chinese medicine composition include: 20-60 parts of Acorus calamus, 30-50 parts of Citrus aurantium, 20-60 parts of Benzoin, and 40-100 parts of Catechu. The traditional Chinese medicine composition of this invention has simple and natural components, and clear efficacy. It can effectively reduce the levels of XOD, SUA, CRE, BUN, TNF-α, IL-6, D-Lac, and DAO in the serum of a mouse model of gout, and significantly reduce the renal index, demonstrating good efficacy in treating hyperuricemia and / or gout.

The invention discloses a uricase mutant. The uricase sequence from aspergillus flavus and the uricase sequence from candida are taken as templates, multiple rounds of random mutation are carried out, sequencing verifies that the key amino acid site of the catalytic center is mutated, and the catalytic activity is enhanced. In-vivo and in-vitro uric acid reducing activities of the two uricase mutants are further verified, and the two uricase mutants can significantly reduce the content of uric acid and are expected to become new uricase drugs for treating hyperuricemia.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating hyperuricemia and a preparation method and application thereof. The traditional Chinese medicine composition comprises the following main active ingredients in parts by mass: 15-25 parts of fried coix seeds, 15-25 parts of rhizoma smilacis glabrae, 15-25 parts of rhizoma alismatis, 5-15 parts of rhizoma atractylodis, 10-15 parts of semen plantaginis, 10-20 parts of yam rhizome, 10-20 parts of dogwood, 10-20 parts of Chinese yam, 10-20 parts of prepared rehmannia roots, 6-12 parts of prepared radix aconiti lateralis praeparata, 10-15 parts of cassia twigs and 6-12 parts of honey-fried licorice roots. The curative effect and safety evaluation research shows that the uric acid reducing effect of the traditional Chinese medicine composition after 12 weeks of treatment is equivalent to that of febuxostat, compared with febuxostat, the traditional Chinese medicine composition can remarkably reduce the occurrence rate of melt crystal pain of a patient during treatment, the liver and kidney functions of the treated patient are not obviously changed, and the safety is good. Research results show that the traditional Chinese medicine composition is remarkable in clinical curative effect and good in safety.

The invention discloses an application of an NRF2 signal channel activator in preparation of a medicine for preventing or treating hyperuricemia-related atherosclerosis, relates to the technical field of medicines, and particularly relates to an application of the NRF2 signal channel activator in preparation of a medicine for preventing or treating hyperuricemia-related atherosclerosis. The NRF2 signal channel activator is used for up-regulating NRF2 protein expression or enhancing transcriptional activity of the NRF2 protein; the NRF2 signal channel activator is used for up-regulating expression of a downstream target gene SLC7A11 and / or GPX4 so as to inhibit ferroptosis of hyperuricemia aortic macrophages; the level of glutathione (GSH) in serum is increased; the malondialdehyde (MDA) and / or iron ion (Fe < 2 + >) level in serum is reduced; nRF2 signal channel activation and macrophage ferroptosis inhibition are associated, and the NRF2 signal channel is applied to prevention and treatment medicines for hyperuricemia-related atherosclerosis, so that development of specific treatment medicines for patients suffering from hyperuricemia-related atherosclerosis is facilitated.

This invention discloses *Pediococcus lactis* TC-4, which simultaneously degrades nucleosides, purines, and uric acid, and its applications. *Pediococcus lactis* ( Pediococcus acidilactici This invention relates to *Pediococcus lactis* TC-4, with accession number GDMCC No: 67936. *Pediococcus lactis* TC-4 of this invention can efficiently degrade three nucleosides (guanosine, adenosine, and inosine), three purines (guanine, xanthine, and hypoxanthine), and uric acid in vitro. *Pediococcus lactis* TC-4 of this invention can effectively reduce serum uric acid levels in broiler chickens, alleviating and treating hyperuricemia. Compared with traditional chemical drugs for treating hyperuricemia and / or gout, this invention has no toxic side effects on the ecological environment, no residue risk, and is green and safe. This invention has been confirmed at multiple levels, including genetic and animal studies, to have no potential harm to humans, demonstrating its advantages of safety and high efficiency.

The application provides an animal Bifidobacterium lactis HNU329 with the ability of reducing uric acid and an application thereof, the animal Bifidobacterium lactis HNU329 has been preserved in the Guangdong Microbial Culture Collection Center (GDMCC), the preservation address is the 5th floor of the 59th building of the courtyard, No. 100, Jiefang Road, Guangzhou, the preservation date is April 22, 2024, the preservation number is GDMCC No: 64546, and the classification and naming are Bifidobacterium animalis subsp. Lactis. The strain has good degradation abilities of nucleosides and purines in vitro, also shows good uric acid reducing ability and anti-inflammatory ability in animal model evaluation, and can regulate the intestinal flora of hyperuricemia mice and improve the symptoms of hyperuricemia. The strain is non-toxic and has no side effects, is safe, and has a wide application prospect.

The invention discloses a fermented chicory composition with xanthine oxidase inhibitory activity as well as a preparation method and application of the fermented chicory composition. The composition is prepared by taking chicory roots as a single plant raw material and fermenting the chicory roots with a composite flora consisting of lactobacillus plantarum, lactobacillus rhamnosus, bifidobacterium adolescentis and streptococcus thermophilus in a viable count ratio of 1: 1: 1: 1. The preparation method comprises the steps of culture medium preparation, inoculated fermentation and post-treatment. Through the synergistic fermentation effect of the specific flora and the chicory substrate, the xanthine oxidase inhibitory activity of the product is remarkably enhanced. Metabonomics analysis shows that various active ingredients such as phenolic acids and prebiotic oligosaccharides are remarkably enriched after fermentation, and a dual-action mechanism of directly inhibiting enzyme activity and indirectly regulating intestinal flora is formed. The composition is safe in raw materials and definite in effect, and can be used for preparing medicines, health-care foods or dietary supplements for prevention or adjuvant treatment of hyperuricemia, gout and related diseases.

The application discloses a metabolic marker, a screening method and application related to gout combined with uric acid nephrolithiasis, and belongs to the technical field of biology. The application analyzes the significant differences of metabolic small molecules in the serum of asymptomatic hyperuricemia and gout combined with uric acid nephrolithiasis patients through a metabolomics method, screens metabolic markers that can be used for predicting gout combined with uric acid nephrolithiasis, and further verifies the sensitivity, specificity and accuracy of the metabolic markers. These findings not only provide markers for early diagnosis and precise treatment of gout combined with uric acid nephrolithiasis, but also provide important basis for understanding the clinical heterogeneity of hyperuricemia and the evolution mechanism thereof.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for activating blood, removing dampness and reducing uric acid and a preparation method and application thereof. The active ingredient of the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 3-10 parts of prepared radix aconiti lateralis preparata, 5-15 parts of rhizoma zingiberis, 5-15 parts of honey-fried licorice root, 5-15 parts of wine-processed radix cyathulae, 10-30 parts of radix salviae miltiorrhizae, 30-60 parts of rhizoma smilacis glabrae, 10-30 parts of plantain herb and 5-15 parts of radix platycodonis. The traditional Chinese medicine has the effects of tonifying deficiency, dispelling excess, promoting blood circulation, removing dampness, reducing uric acid and strengthening the body resistance, not only strengthens healthy qi to treat root causes, but also promotes blood circulation, removes dampness to treat symptoms, and achieves the effect of treating both symptoms and root causes. Clinical research shows that the traditional Chinese medicine composition disclosed by the invention can be used for reducing the level of uric acid in fasting serum of a patient with hyperuricemia by promoting blood circulation, removing dampness and supporting healthy qi, so that the purpose of effectively treating hyperuricemia is achieved.

The application discloses camel milk hypouricemic peptides with a hypouricemic effect and application thereof, and the amino acid sequence of the camel milk hypouricemic peptides is QPWMQ. The camel milk hypouricemic peptides can significantly inhibit the activity of xanthine oxidase (XOD) and / or adenosine deaminase (ADA), reduce the uric acid concentration in the body, maintain the normal level of uric acid in blood, and prevent and treat hyperuricemia; and the application fully excavates small-molecule bioactive substances of camel milk, and improves the nutritional value and economic value of camel milk.

The invention belongs to the technical field of biotechnology and medicine, and particularly relates to application of an Anapc11 gene / protein to screening of drugs for treating hyperuricemia-related multi-organ dysfunction. According to the invention, the Anapc11 gene is used as a molecular target or a drug action target, and is used for screening or preparing drugs for treating multi-organ dysfunction (including liver injury, testis dysfunction, intestinal barrier destruction and the like) caused by hyperuricemia. The invention provides a new application of the cell cycle promoting complex subunit E3 ubiquitin ligase Anapc11 gene, provides a new molecular target for treating hyperuricemia related multi-organ dysfunction, and breaks through the limitation that the existing uric acid reducing medicine is only limited to a metabolic link; a new direction and a good application prospect are provided for developing innovative medicines with organ protection effects.

This invention belongs to the technical field of food-medicine homology compositions, specifically relating to a food-medicine homology composition for assisting in the improvement of hyperuricemia and its application. By weight, the food-medicine homology composition is made from the following raw materials: 3-15 parts kudzu root, 2-4 parts honeysuckle, 5-10 parts codonopsis, 2-4 parts astragalus, 6-8 parts coix seed, 3-5 parts red adzuki bean, and 2-4 parts licorice. The formulation of the food-medicine homology composition of this invention is based on the core principles of strengthening the spleen and kidneys, clearing heat and removing dampness, and resolving phlegm and removing blood stasis. All raw materials used in the food-medicine homology composition are food-medicine homology materials, and compared with chemical drugs, they cause less liver damage in the treatment of hyperuricemia. This invention mainly addresses the problem of high liver damage caused by chemical drugs used in the treatment of hyperuricemia.

This invention discloses urinary metabolic biomarkers for hyperuricemia and their applications, relating to the field of metabolomics technology. It aims to overcome the shortcomings of traditional serum uric acid detection, such as susceptibility to interference, insufficient early warning capabilities, and a lack of sensitive, specific, and non-invasive biomarkers. The urinary metabolic biomarker is at least one of L-kynurenine, indole, and betaine, which can be used to prepare reagents or kits. The assessment system includes a sample analysis unit and a risk assessment model. This invention enables non-invasive and convenient detection of hyperuricemia, accurately captures early metabolic abnormalities, provides reliable risk stratification, and supports clinical auxiliary diagnosis and pathogenesis research.

The invention provides a pharmaceutical composition for preventing, treating or relieving uric acid metabolic disorder and application, the pharmaceutical composition comprises a xanthine oxidase inhibitor and a URAT1 inhibitor, and the xanthine oxidase inhibitor is selected from teguxostat or febuxostat; the URAT1 inhibitor is selected from the group consisting of dotenod, Velnod, Lesinurad, Ruzinurad, SAP-001, ABP-671, SHR4640 and the like. The pharmaceutical composition provided by the invention can effectively reduce the concentration of uric acid in serum of a patient with hyperuricemia, so that the hyperuricemia is effectively prevented, treated or relieved. Compared with a single drug and the sum thereof, the combined drug composition can effectively inhibit serum uric acid, serum creatinine and urea nitrogen.

A polymorphic form of a GLP-1R agonist compound (III), a preparation method therefor and a use thereof are provided. Compared with an amorphous form of compound (III), the polymorphic form has higher stability and better processability, and is more suitable for preparing a drug for preventing or treating diseases related to a GLP-1R target and a signaling pathway thereof, such as type 2 diabetes, prediabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, kidney disease, gout, hyperhematuria, cardiovascular disease, etc.

The application belongs to the technical field of biology and relates to a high-activity and high-humanization rate uric acid oxidase mutant. The high-activity and high-humanization rate uric acid oxidase mutant is a human uric acid oxidase mutant obtained by mutation of an inactivated human uric acid oxidase with an amino acid sequence of SEQ ID NO. 1, which has amino acid substitutions at positions 83, 119, 121, 151, 222, 232, 233, 240 and 252, also has amino acid substitutions at positions 208 and 219, and further has an amino acid substitution at position 112. The high-activity and high-humanization rate uric acid oxidase mutant has high homology with a theoretical amino acid sequence of human uric acid oxidase, has high activity, is more suitable for long-term use in the treatment of hyperuricemia and gout in the clinic, and can be used for preparing a drug for treating hyperuricemia and gout.

The invention relates to the technical field of microorganisms and biological medicines, in particular to triple probiotics as well as a preparation method and application thereof, and the triple probiotics comprise at least one probiotic of bacillus, lactobacillus acidophilus and bifidobacterium longum. The triple probiotics provided by the invention form an'oxygen consumption-enzyme production-acid production 'synergistic chain, and through synergistic degradation of uric acid, inhibition of excessive growth of conditioned pathogens and enhancement of intestinal barrier functions, the blood uric acid level of patients with asymptomatic hyperuricemia is reduced, the alpha-diversity of intestinal tracts is improved, the abundance of butyric acid producing bacteria is improved, and the content of the butyric acid producing bacteria is improved. The ratio of escherichia coli to shigella is reduced; sIBO is effectively relieved or reversed, and digestive tract symptoms such as abdominal distension and exhaust are reduced. In addition, the triple probiotics avoid liver and kidney toxicity caused by chemical drugs, and are suitable for long-term administration.

The invention relates to the field of uric acid reducing medicines, and discloses a compound with a uric acid reducing effect as well as a preparation method and application thereof. According to the compound with the uric acid reducing effect, proanthocyanidin B1 serves as a raw material, glycosylation modification is conducted on the site 7 of an A ring of the proanthocyanidin B1, proanthocyanidin B1-7-O-beta-D-glucopyranoside is obtained, the IC50 value of the inhibiting effect of the proanthocyanidin B1-7-O-beta-D-glucopyranoside on xanthine oxidase is reduced, and therefore the uric acid reducing effect of the proanthocyanidin B1 is improved. And the glucose at the No.7 site is modified, so that the metabolic inactivation path is reduced, and the in-vivo half-life period is prolonged. A new strategy and a clinical research basis are provided for prevention or treatment of the hyperuricemia, a scientific basis is further provided for guiding clinical medication for treating the hyperuricemia, and the application prospect is good.

The invention belongs to the technical field of medicines, and discloses a substituted pyridine dipyrrole compound as well as a preparation method and medicinal application thereof. Specifically, the invention discloses a substituted pyridine dipyrrole compound as shown in a formula (I), physiologically acceptable salts of the substituted pyridine dipyrrole compound, a preparation method of the compound, application of the compound in preparation of URAT1 inhibitors, a pharmaceutical preparation containing the compound, and application of the compound in preparation of medicines for preventing and treating hyperuricemia and gout, and particularly discloses a substituted pyridine dipyrrole compound as shown in the formula (I), physiologically acceptable salts of the substituted pyridine dipyrrole compound, a preparation method of the compound and application of the compound in preparation of medicines for preventing and treating hyperuricemia and gout.

The invention discloses a preparation method and application of hempseed (-)-epicatechin-3-O-gallate, and belongs to the technical field of biology. According to the preparation method disclosed by the invention, the non-ester catechin and the ester-rich catechin are separated by adopting the mixed solvents of the ethanol, the methanol and the isopropanol, so that the extraction rate of the (-)-epicatechin-3-O-gallate can be improved (97% or above). Meanwhile, recrystallization is carried out by adopting organic solvents of methanol, normal propyl alcohol and isopropyl alcohol after extraction, so that the purity of the hempseed (-)-epicatechin-3-O-gallate can be improved (98% or above). The extracted epicatechin-3-O-gallate (ECG) is a natural antioxidant, has good biological activity, and has a good treatment effect on prevention and treatment of the hyperuricemia nephropathy.

The invention discloses a siRNA (small interfering Ribonucleic Acid) for inhibiting the gene expression of a urate transporter 1 (URAT1) in a human body cell, and particularly discloses a siRNA (small interfering Ribonucleic Acid) for inhibiting the gene expression of the URAT1 in the human body cell. According to the invention, a plurality of siRNAs which can be used for inhibiting URAT1 expression are screened, and on the basis, proper modification is carried out to improve the silence ability of a target. The medicine taking the siRNA as the activity is expected to be clinically applied to prevention and treatment of diseases such as gout, hyperuricemia, gouty arthritis, kidney stone and the like related to URAT1 targets.

The present application relates to the technical field of hyperuricemia modeling, and particularly relates to a method for inducing and constructing a cynomolgus monkey hyperuricemia model and application thereof, comprising the following steps: S1: selecting male cynomolgus monkeys as model animals; S2: administering an inducing agent to the experimental animals, wherein the inducing agent is composed of hydrochlorothiazide, potassium oxonate and adenine. The inducing agent is added to ordinary monkey feed for normal feeding of the experimental animals, the intake dose of hydrochlorothiazide is 0.1 g / kg / day, the intake dose of potassium oxonate is 0.2 g / kg / day, the intake dose of adenine is 0.1 g / kg / day, and 10% fructose water is used to replace ordinary drinking water at the same time. The present application can induce a stable hyperuricemia state in the cynomolgus monkey body by means of dietary induction, combined use of hydrochlorothiazide, potassium oxonate and adenine, compared with a traditional model induced by a single intraperitoneal injection of a drug, the present application better simulates the pathogenic cause of human hyperuricemia, and is easier to operate.

The present application discloses a human faecal blautia strain capable of colonizing in an anaerobic environment of the intestinal tract and an application thereof, and relates to the technical field of microorganisms.The present application provides a strain with a uric acid degradation function, the human faecal blautia strain GH001, which has the effects of reducing uric acid level, preventing and treating hyperuricemia and gout, and the human faecal blautia strain GH001 also has the effect of relieving kidney damage to a certain extent.The present application provides a new probiotic or drug material for the treatment of hyperuricemia and related diseases.In addition, the strain has no obvious influence on the indicators of the sample body, which proves that the strain has the characteristics of high safety and can be widely applied in the medical field.